Supriya Lifescience Ltd Analyst Rating
based on 1 analysts
100.00%
Buy
0.00%
Hold
0.00%
Sell
Based on 1 analysts offering long term price targets for Supriya Lifescience Ltd. An average target of ₹644
Source: S&P Global Market Intelligence
Supriya Lifescience Ltd Share analysis
Supriya Lifescience Ltd price forecast by 1 analysts
Downside of
High
₹644
Target
₹644.00
Low
₹644
Supriya Lifescience Ltd target price ₹644, a slight downside of -12.7% compared to current price of ₹737.7. According to 1 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Supriya Lifescience Ltd revenue growth forecast
Expected growth rate Q1, FY2026:0
Forecast
Actual
Including amortisation and stock based compensations
Supriya Lifescience Ltd EPS growth forecast
EPS estimate Q1, FY2026:0
Forecast
Actual
Source: S&P Global Market Intelligence
Supriya Lifescience Ltd Performance
Day's Low
Day's High
₹732₹76152 Week's Low
52 Week's High
₹269₹835.2
| Returns % | |
| 1 Month Return | + 14.48 % |
| 3 Month Return | + 14.04 % |
| 1 Year Return | + 162.48 % |
| Market Stats | |
| Previous Close | ₹756.15 |
| Open | ₹759.10 |
| Volume | 2.54L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹6,085.71Cr |
Supriya Lifescience Ltd Key Statistics
| P/E Ratio | 0 |
| PEG Ratio | 0 |
| Market Cap | ₹6,085.71 Cr |
| P/B Ratio | 3.27 |
| EPS | 0 |
| Dividend Yield | 0 |
| Sector | Pharmaceuticals |
| ROE | 15.73 |
Supriya Lifescience Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹6,085.71 Cr | 17.75% | 0.50 | NA | NA | |
| NA | ₹2,638.33 Cr | 204.82% | 0.62 | ₹43 Cr | ₹381 Cr | |
| NA | ₹34.08 Cr | 23.7% | 0.52 | NA | NA | |
| NA | ₹148.16 Cr | 156.39% | 0.51 | NA | NA | |
| NA | ₹15.00 Cr | 30.85% | 0.70 | -₹1 Cr | ₹27 Cr |
Supriya Lifescience Ltd Mutual Fund Holdings
About Supriya Lifescience Ltd
Share Price: ₹737.70 per share as on 13 Dec, 2024 04:01 PM
Market Capitalisation: ₹6,085.71Cr as of today
Listing date: 28 Dec, 2021
Chairperson Name: Satish Waman Wagh
| Organisation | Supriya Lifescience Ltd |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Supriya Lifescience Ltd
Supriya Lifescience Gains ANVISA Approval for Drug - 09 Dec, 2024
Supriya Lifescience Ltd has secured ANVISA approval for Esketamine Hydrochloride, becoming the first Indian company to do so. This milestone, along with a patent for a cost-effective atorvastatin synthesis, positions the company for growth in the LATAM market. Shares rose 1.16% following the announcement.
Insights on Supriya Lifescience Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 0.13% to 0.62% in Sep 2024 quarter
- POSITIVE IMPACT
Best in 1 Year
In the last 1 year, SUPRIYA has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 4.95% to 6.03% in Sep 2024 quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 68.30% of holdings in Sep 2024 quarter
NEGATIVE IMPACTPrice Dip
In the last 7 days, SUPRIYA stock has moved down by -5.9%
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 21.27% to 20.23% in Sep 2024 quarter
Supriya Lifescience Ltd Financials
Index Inclusions
Supriya Lifescience Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 68.3% | 0.00 | |
| Foreign Institutions | 6.03% | 21.78 | |
| Mutual Funds | 0.62% | 369.71 | |
| Retail Investors | 20.23% | ||
| Others | 4.83% |
Supriya Lifescience Ltd Key Indicators
Supriya Lifescience Ltd Earnings and Dividends
Supriya Lifescience Ltd Earnings Results
Supriya Lifescience Ltd’s net profit jumped 93.26% since last year same period to ₹46.15Cr in the Q2 2024-2025. On a quarterly growth basis, Supriya Lifescience Ltd has generated 3.38% jump in its net profits since last 3-months.
Read More about Earnings ResultsSupriya Lifescience Ltd Dividends May,2024
In the quarter ending March 2024, Supriya Lifescience Ltd has declared dividend of ₹0.80 - translating a dividend yield of 0.11%.
Read More about Dividends
Supriya Lifescience Ltd Technicals Summary
Bearish
Neutral
Bullish
Supriya Lifescience Ltd is currently in a Neutral trading position according to technical analysis indicators.
FAQs on Supriya Lifescience Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Supriya Lifescience Ltd shares.
Supriya Lifescience Ltd (SUPRIYA) share price today is ₹737.7
Supriya Lifescience Ltd is listed on NSE
Supriya Lifescience Ltd is listed on BSE
- Today’s highest price of Supriya Lifescience Ltd is ₹761.
- Today’s lowest price of Supriya Lifescience Ltd is ₹732.
Today’s traded volume of Supriya Lifescience Ltd(SUPRIYA) is 2.54L.
Today’s market capitalisation of Supriya Lifescience Ltd(SUPRIYA) is ₹6085.71Cr.
| Supriya Lifescience Ltd(SUPRIYA | Price |
|---|---|
52 Week High | ₹835.2 |
52 Week Low | ₹269 |
Supriya Lifescience Ltd(SUPRIYA) share price is ₹737.7. It is down -11.67% from its 52 Week High price of ₹835.2
Supriya Lifescience Ltd(SUPRIYA) share price is ₹737.7. It is up 174.24% from its 52 Week Low price of ₹269
| Supriya Lifescience Ltd(SUPRIYA | Returns |
|---|---|
1 Day Returns | -18.45% |
1 Month Returns | 14.48% |
3 Month Returns | 14.04% |
1 Year Returns | 162.48% |